Dai Dingwei, Coetzer Henriette, Zion Sean R, Malecki Michael J
CVS Health Clinical Trial Services, LLC, Woonsocket, Rhode Island, USA.
Blue Note Therapeutics, Inc., San Francisco, California, USA.
J Health Econ Outcomes Res. 2023 Mar 28;10(1):68-76. doi: 10.36469/001c.70238. eCollection 2023.
Breast cancer is the most common cancer among women in the United States. Newly diagnosed patients with breast cancer often experience anxiety, depression, and stress. However, the impact of psychological distress on healthcare resource utilization (HCRU) and costs has not been adequately assessed. To evaluate the incidence and prevalence of anxiety, depression, and stress reaction/adjustment disorder among patients newly diagnosed with breast cancer, to examine HCRU and costs, and to assess the association of these psychiatric disorders with costs. This retrospective observational cohort study was conducted using a large US administrative claims database with an index date of newly diagnosed breast cancer. Demographics and comorbidities (including anxiety, depression, and stress reaction/adjustment disorder) were assessed using data collected 12 months before and after the index date. HCRU and costs were assessed using data collected 12 months after the index date. Generalized linear regressions were performed to examine the association between healthcare costs and anxiety, depression, and stress reaction/adjustment disorder. Of 6392 patients with newly diagnosed breast cancer, 38.2% were diagnosed with psychiatric disorders including anxiety (27.7%), depression (21.9%), or stress reaction/adjustment disorder (6%). The incidence of these psychiatric disorders was 15% and the prevalence was 23.2%. Patients with anxiety, depression, or stress reaction/adjustment disorder had higher rates of several types of HCRU ( < .0001) and higher total all-cause costs compared with patients without these psychiatric disorders ( < .0001). Patients with incident anxiety, depression, or stress reaction/adjustment disorder incurred higher all-cause costs in the first year following breast cancer diagnosis than those with prevalent anxiety, depression, or stress reaction/adjustment disorder ( < .0003), or those without these psychiatric disorders ( < .0001). Of patients with anxiety, depression, or stress reaction/adjustment disorder, those with incident psychiatric disorders had higher healthcare costs, suggesting that new-onset psychological distress may contribute to higher costs incurred by the payer. Timely treatment of psychiatric disorders in this population may improve clinical outcomes and reduce HCRU and costs. Anxiety, depression, and stress reaction/adjustment disorder were common among patients newly diagnosed with breast cancer and were associated with increased healthcare costs in the first year following breast cancer diagnosis.
乳腺癌是美国女性中最常见的癌症。新确诊的乳腺癌患者常经历焦虑、抑郁和压力。然而,心理困扰对医疗资源利用(HCRU)和成本的影响尚未得到充分评估。为了评估新确诊乳腺癌患者中焦虑、抑郁和应激反应/适应障碍的发病率和患病率,研究HCRU和成本,并评估这些精神障碍与成本之间的关联。这项回顾性观察队列研究使用了一个大型美国行政索赔数据库,索引日期为新确诊的乳腺癌。使用索引日期前后12个月收集的数据评估人口统计学和合并症(包括焦虑、抑郁和应激反应/适应障碍)。使用索引日期后12个月收集的数据评估HCRU和成本。进行广义线性回归以研究医疗成本与焦虑、抑郁和应激反应/适应障碍之间的关联。在6392例新确诊的乳腺癌患者中,38.2%被诊断患有精神障碍,包括焦虑(27.7%)、抑郁(21.9%)或应激反应/适应障碍(6%)。这些精神障碍的发病率为15%,患病率为23.2%。与没有这些精神障碍的患者相比,患有焦虑、抑郁或应激反应/适应障碍的患者几种类型的HCRU发生率更高(<0.0001),全因总成本更高(<0.0001)。新发生焦虑、抑郁或应激反应/适应障碍的患者在乳腺癌诊断后的第一年比患有现患焦虑、抑郁或应激反应/适应障碍的患者(<0.0003)或没有这些精神障碍的患者(<0.0001)产生更高的全因成本。在患有焦虑、抑郁或应激反应/适应障碍的患者中,新发生精神障碍的患者医疗成本更高,这表明新出现的心理困扰可能导致支付方产生更高的成本。及时治疗该人群的精神障碍可能改善临床结局并降低HCRU和成本。焦虑、抑郁和应激反应/适应障碍在新确诊的乳腺癌患者中很常见,并且与乳腺癌诊断后第一年医疗成本增加有关。